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Abstract
Background: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on
chromosome 1q21-25. Both PKLR encoding the liver pyruvate kinase and NOS1AP encoding the
nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this
chromosomal region and are thus positional candidates for the observed linkage peak. The C-allele
of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with
type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with
a combined odds ratio (OR) of 1.33 [1.16–1.54] and 1.53 [1.28–1.81], respectively. Our aim was
to validate these findings by investigating the impact of the two variants on type 2 diabetes and
related quantitative metabolic phenotypes in a large study sample of Danes. Further, we intended
to expand the analyses by examining the effect of the variants in relation to overweight and obesity.
Methods:  PKLR  rs3020781 and NOS1AP  rs7538490 were genotyped, using TaqMan allelic
discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals,
respectively. The participants were ascertained from four different study groups; the population-
based Inter99 cohort (nPKLR = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (nPKLR = 1,873,
nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, nNOS1AP
= 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR =
8,367, nNOS1AP = 8,435).
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Results: In case-control studies we evaluated the potential association between rs3020781 and
rs7538490 and type 2 diabetes and obesity. No significant associations were observed for type 2
diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96–1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93–
1.06]). Neither did we show association with overweight or obesity. Additionally, the PKLR and the
NOS1AP  genotypes were demonstrated not to have a major influence on diabetes-related
quantitative metabolic phenotypes.
Conclusion: We failed to provide evidence of an association between PKLR  rs3020781 and
NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic
phenotypes in large-scale studies of Danes.
Background
Type 2 diabetes (T2D) is a complex metabolic disease,
where several tissues and organs, including pancreatic β-
cells, skeletal muscle, adipose tissue, liver and the central
nervous system have been suggested to be directly or indi-
rectly involved in the pathogenesis [1].
Several independent studies have shown evidence for
linkage between chromosome 1q21-25 and T2D in multi-
ple ethnicities [2-14]. Both PKLR encoding the liver pyru-
vate kinase and NOS1AP  encoding the nitric oxide
synthase 1 (neuronal) adaptor protein (CAPON), are
located in the 1q21-25 region and are therefore positional
candidate genes for T2D susceptibility. The puryvate
kinase enzyme catalyses the last step in glycolysis convert-
ing phosphoenolpyruvate to pyruvate under the genera-
tion of ATP. PKLR is, in addition to the liver, expressed in
pancreatic  β-cells, the kidneys and the small intestine
[15], and its expression is upregulated by glucose through
a carbohydrate response element in the promoter [16].
Moreover, a binding site for hepatocyte nuclear factor 1-α
is located in the PKLR promoter and patients with matu-
rity-onset diabetes of the young type 1 and 3 show
decreased expression of the gene [17,18]. Hence, PKLR is
a strong biological candidate gene for impaired blood glu-
cose regulation and thus T2D. The CAPON protein binds
nitric oxide synthase, which results in downregulation of
N-methyl-D-aspartate receptor-mediated glutamate sig-
nalling [19], however, the link between dysfunctional
CAPON protein and T2D is as yet unexplained.
A substantial number of genes, in this very gene-dense
1q21-25 region, have already been investigated for sus-
ceptibility to T2D, however, none have so far explained
the observed linkage [1]. As a part of The International
Type 2 Diabetes 1q Consortium 5,285 single-nucleotide
polymorphisms (SNPs), covering 22.7 Mb of the 1q link-
age region were genotyped in 1,000 cases and 1,198
matched controls from four different European-descent
populations.
Two SNPs, rs3020781 in PKLR and rs7538490 in NOS1AP
were reported to associate with T2D. Applying an additive
model the C-allele of PKLR rs3020781 associated with
T2D with an odds ratio (OR) of 1.33 [1.16–1.54] (p =
1·10-6), and under a dominant model the T-allele of
NOS1AP rs7538490 associated with T2D with an OR of
1.53 [1.28–1.81] (p = 2·10-6)[38]. PKLR has previously
been examined in two independent studies, where four
SNPs, (rs3020781, rs2071053, rs1052176, rs1052177),
showed association with T2D when analysing a total 909
individuals of European descent [20,21]. No further asso-
ciation studies regarding the role of NOS1AP  in T2D
pathogenesis have been performed.
The aim of the present study was to validate the associa-
tion of PKLR rs3020781 and NOS1AP rs7538490 with
T2D. In addition we intend to expand with analyses of
overweight and obesity and the relationship with diabe-
tes-related metabolic quantitative phenotypes.
Methods
Subjects
PKLR rs3020781 and NOS1AP rs7538490 were success-
fully genotyped in 16,801 and 16,913 Danes, respectively,
involving four study groups 1) the population-based
Inter99 cohort (ClinicalTrials.gov ID no: NCT00289237)
(nPKLR = 5,962, nNOS1AP = 6,008), with an average age of 46
± 8 years and a mean BMI of 26.2 ± 4.6 kg/m2, sampled at
the Research Centre for Prevention and Health [22] 2)
unrelated T2D patients (nPKLR = 1,873, nNOS1AP = 1,874),
with an average age of 62 ± 11 years and a mean BMI of
30.0 ± 5.6 kg/m2, sampled through the out-patient clinic
at Steno Diabetes Center 3) a population-based group of
unrelated middle-aged individuals (nPKLR = 599, nNOS1AP =
596), with an average age of 59 ± 8 years and a mean BMI
of 26.5 ± 4.2 kg/m2, examined at Steno Diabetes Center 4)
the ADDITION Denmark screening study cohort (Clini-
calTrials.gov ID no: NCT00237548) (nPKLR  = 8,367,
nNOS1AP = 8,435), with an average age of 60 ± 7 years and
a mean BMI of 28.6 ± 4.9 kg/m2, sampled by Department
of General Practice at University of Aarhus [23]. The dif-
ferent study groups are further described in Additional file
1. In study group 1 and 3 all non-diabetic individuals
underwent a standard 75 g oral glucose tolerance test
(OGTT) and only glucose-tolerant and normoglycaemicBMC Medical Genetics 2008, 9:118 http://www.biomedcentral.com/1471-2350/9/118
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individuals were included as control subjects in the case-
control study of T2D. Analyses of quantitative metabolic
phenotypes were performed in the population-based
Inter99 cohort exclusively, excluding T2D patients receiv-
ing pharmalogical treatment. Informed written consent
was obtained from all individuals before participation.
The studies were approved by the regional Ethical Com-
mittees (Ethics Committee, Copenhagen County for study
group 1, 2 and 3 and Ethics Committee, Aarhus County
for study group 4) and were in accordance with the prin-
ciples of the Helsinki Declaration. T2D and normal glucose
tolerance (NGT) were defined according to the World
Health Organization [24].
Biochemical and anthropometrical measurements
In all study groups body weight and height were measured
in light indoor clothes and without shoes [22,23]. In
study groups 1 and 3 serum insulin and plasma glucose
were measured at fasting and 30 and 120 minutes after an
OGTT. Serum insulin levels excluding des(31,32)- and
intact proinsulin were measured using the AutoDELFIA
insulin kit (Perkin-Elmer, Wallac, Turku, Finland).
Plasma glucose was analysed using a glucose oxidase
method (Granutest; Merck, Darmstadt, Germany) [25].
The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as fasting plasma glucose
(mmol/l) multiplied by fasting serum insulin (pmol/l)
divided by 22.5. The BIGTT insulin sensitivity index
(BIGTT-Si) and BIGTT acute insulin response (BIGTT-AIR)
were calculated as described [26,27].
Genotyping
PKLR  rs3020781 and NOS1AP  rs7538490 were geno-
typed using Taqman allelic discrimination (KBioscience,
Herts, UK). Discordances between 1,202 random dupli-
cate samples were 0.1% and 0.2%, respectively, and the
genotyping success rates were 96.3% and 96.8%, respec-
tively. Both genotype groups obeyed Hardy-Weinberg
equilibrium (p > 0.05).
Statistical analysis
Fisher's exact test was applied to examine differences in
allele frequencies (AF) between affected and unaffected
individuals. A general linear model was used to test quan-
titative metabolic variables for differences between geno-
type groups assuming an additive (Add) model for PKLR
rs3020781, and a dominant (Dom) model for NOS1AP
rs7538490. Values of plasma glucose, serum insulin,
HOMA-IR and BIGTT-AIR were logarithmically trans-
formed before statistical analysis to obtain normal distri-
bution. Adjustment for sex, age and BMI was applied
when appropriate. All analyses were performed in RGui
version 2.5.0 [28], and p-values < 0.05 were considered
significant. Statistical power was determined using the
CaTS power calculator version 0.0.2. A test for homogene-
ity between the population-based Inter99 cohort, the T2D
patients and the population-based sample from Steno
Diabetes Center and the ADDITION Denmark screening
study cohort, was performed by means of the Mantel-
Haenszel method (fixed effects model) for both geno-
types, revealing no significant heterogeneity between
study groups (rs3020781: p = 0.8, rs7538490: p = 0.4).
Results and discussion
The minor allele frequencies (MAF) of the PKLR
rs3020781 C-allele and the NOS1AP rs7538490 T-allele
were 26.2% and 28.0%, respectively, and comparable to
the 32.5% and 29.7%, reported for the HapMap CEU
population. Using the population-based Inter99 cohort as
reference the prevalence of T2D is estimated to 6% in the
Danish population of middle-aged people. Combining
the four study samples, gives us a statistical power of
100% observing an association with T2D with a relative
risk above 1.3, and a MAF as reported for the two variants
assuming either an additive or a dominant model. The
potential associations between PKLR  rs3020781 and
NOS1AP rs7538490 and T2D were evaluated in case-con-
trol studies including 8,410 and 8,447 individuals, respec-
tively. No difference in allele frequencies between T2D
patients and glucose-tolerant subjects were found for
either SNP (rs3020781: pAF = 0.49, OR [95% CI] = 1.02
[0.96–1.10]; rs7538490: pAF = 0.84, OR [95% CI] = 0.99
[0.93–1.06]), Table 1.
Case-control studies comparing allele frequencies
between body mass index (BMI) defined normal weight
(BMI < 25 kg/m2) individuals and overweight (25 kg/m2
≤ BMI < 30 kg/m2) or obese (BMI ≥ 30 kg/m2) individuals,
respectively, were performed in the combined study sam-
ple including T2D patients. No statistically significant
association with overweight or obesity were demonstrated
for PKLR rs3020781 (overweight: pAF = 0.49, OR [95% CI]
= 0.98 [0.92–1.04]; obesity: pAF = 0.81, OR [95% CI] =
0.99 [0.93–1.06]) nor for NOS1AP  rs7538490 (over-
weight: pAF = 0.48, OR [95% CI] = 0.95 [0.83–1.09]; obes-
ity: pAF = 0.68, OR [95% CI] = 0.99 [0.93–1.05]), Table 1.
As pharmacological treatment can influence on BMI, we
additionally performed case-control studies of overweight
and obesity considering T2D patients and treatment-naïve
indviduals separately, however, neither variant showed
association with overweight or obesity when stratifying
according to glucose tolerance status (data not shown).
Furthermore, we investigated PKLR  rs3020781 and
NOS1AP  rs7538490 for influence on diabetes-related
quantitative metabolic phenotypes in 5,590 and 5,630
treatment-naïve Danish people from the population-
based Inter99 cohort, respectively. No association with
plasma glucose or serum insulin levels at fasting, 30 or
120 min during an OGTT or with OGTT-derived surrogateBMC Medical Genetics 2008, 9:118 http://www.biomedcentral.com/1471-2350/9/118
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indices of insulin sensitivity or beta-cell function was
demonstrated, Table 2. To evaluate the effect of the vari-
ants in individuals without impaired blood glucose regu-
lation, analyses of quantitative metabolic phenotypes
were conducted in the population-based Inter99 cohort
including only glucose-tolerant individuals (nPKLR  =
4,248, nNOS1AP = 4,269). However, no significant differ-
ences in genotype distribution of the two SNPs were dem-
onstrated (data not shown).
Despite successful identification of several T2D suscepti-
ble genes only a small percentage of T2D heritability is
explained, thus, more T2D genes are to be found.
Originally two clusters of SNPs located within the T2D
linkage peak were identified by The International Type 2
Diabetes 1q Consortium to associate with T2D among a
total of 5,285 SNPs tagging the linkage peak. The first clus-
ter of 9 SNPs were located in a linkage disequilibrium
(LD) region including PKLR while the second cluster of 4
SNPs resided within NOS1AP. Replication of such poten-
tial associations, in statistically well-powered studies, is
essential to substantiate the initial findings. Therefore, we
aimed specifically at replicating the strongest associations
in the two clusters of SNPs within PKLR and NOS1AP,
which are rs3020781 and rs7538490, respectively. How-
ever, we did not show any association with T2D for either
Table 1: Case-control studies of PKLR rs3020781 and NOS1AP rs7538490 in relation to type 2 diabetes, overweight and obesity
PKLR rs3020781
n 
(men/women)
TT
(%)
TC
(%)
CC
(%)
MAF
(95% CI)
pAF OR
(95% CI)
NGT 4,736
(2,209/2,527)
2,602 (55) 1,812 (38) 322
(7)
25.9
(25.0–26.8)
0.49 1.02
(0.96–1.10)
T2D 3,674
(2,187/1,487)
1,998 (54) 1,412 (39) 264
(7)
26.4
(25.4–27.4)
BMI < 25 (kg/m2) 5,036
(2,111/2,925)
2,732
(54)
1,952
(39)
352
(7)
26.4
(25.5–27.2)
25 ≤ BMI < 30 (kg/m2) 6,985
(4,359/2,626)
3,821
(55)
2,700
(39)
464
(6)
26.0
(25.2–26.7)
0.49 0.98
(0.92–1.04)
BMI ≤ 30 (kg/m2) 4,780
(2,467/2,313)
2,612
(55)
1,845
(38)
323
(7)
26.2
(25.3–27.1)
0.81 0.99
(0.93–1.06)
NOS1AP rs7538490
n (men/women) CC
(%)
CT
(%)
TT
(%)
MAF
(95% CI)
pAF OR
(95% CI)
NGT 4,755
(2,218/2,537)
2,479 (52) 1,914 (40) 362
(8)
27.7
(26.8–28.7)
0.84 0.99
(0.93–1.06)
T2D 3,692
(2,200/1,492)
1,954 (53) 1,439 (39) 299
(8)
27.6
(26.6–28.6)
BMI < 25 (kg/m2) 5,064
(2,128/2,936)
2,635
(52)
2,013
(40)
416
(8)
28.1
(27.2–29.0)
25 ≤ BMI < 30 (kg/m2) 7,030 (4,384/2,646) 3,628
(51)
2,857
(41)
545
(8)
28.1
(27.3–28.8)
0.48 0.95
(0.83–1.09)
BMI ≥ 30 (kg/m2) 4,819
(2,490/2,329)
2,517
(52)
1,923
(40)
379
(8)
27.8
(26.9–28.7)
0.68 0.99
(0.93–1.05)
Data are number of individuals, divided into genotype groups (% in each group), and frequencies of the minor allele (MAF) in percentages. Fisher's 
exact test was used to compare allele frequencies (pAF). The odds ratios (OR) and 95% confidence interval (CI) are given for comparison of allele 
frequency. NGT: individuals with normal glucose tolerance, T2D: type 2 diabetic patients.BMC Medical Genetics 2008, 9:118 http://www.biomedcentral.com/1471-2350/9/118
Page 5 of 8
(page number not for citation purposes)
of the two variants, despite having the statistical power to
detect the reported effect sizes. Neither did we find an
association with pertinent metabolic phenotypes, which
could indicate an impaired blood glucose regulation ulti-
mately leading to T2D.
From our studies we can exclude rs3020781 and
rs7538490 as T2D susceptibility variants in the Danish
population, but PKLR and NOS1AP may still represent
true T2D susceptibility loci. That PKLR represents a true
T2D candidate gene, is supported by a study analysing two
SNPs (rs1052176 and rs1052177) within PKLR, both
showing association with T2D and both being in perfect
LD with rs3020781 according to HapMap [21]. HapMap
further outlined that rs3020781 is located at the border of
a LD block near a recombination hotspot. Therefore, if the
LD pattern is slightly shifted in our population, compared
to the populations in which association is observed,
Table 2: Quantitative metabolic characteristics of 5,590 and 5,630 treatment-naïve individuals from the population-based Inter99 
cohort, stratified according to the PKLR rs3020781 genotype and the NOS1AP rs7538490 genotype, respectively
PKLR rs3020781 NOS1AP rs7538490
TT TC CC pAdd CC CT TT pDom
n
(men/women)
3,065
(1,544/1,521)
2,169
(1,062/1,107)
356
(180/176)
2,954
(1,474/1,480)
2,238
(1,109/1,129)
438
(221/217)
Age (years) 46 ± 8 46 ± 8 45 ± 8 46 ± 8 46 ± 8 46 ± 8
BMI (kg/m2) 26.2 ± 4.6 26.2 ± 4.5 25.9 ± 4.3 0.58 26.2 ± 4.5 26.3 ± 4.6 26.1 ± 4.6 0.52
Plasma glucose (mmol/l)
Fasting 5.5 ± 0.8 5.6 ± 0.9 5.5 ± 0.6 0.88 5.5 ± 0.7 5.5 ± 0.8 5.6 ± 1.1 0.46
30-min 8.7 ± 1.9 8.7 ± 1.9 8.6 ± 1.9 0.31 8.7 ± 1.9 8.7 ± 1.9 8.7 ± 1.8 0.90
120-min 6.2 ± 2.2 6.2 ± 2.1 6 ± 2.0 0.33 6.2 ± 2.1 6.2 ± 2.2 6.3 ± 2.1 0.22
Serum insulin (pmol/l)
Fasting 34
(23–50)
35
(24–52)
31
(24–47)
0.21 34
(24–51)
34
(23–51)
34
(24–51)
0.14
30-min 243
(173–350)
248
(177–355)
246
(176–355)
0.29 244
(175–351)
247
(176–354)
248
(173–360)
0.67
120-min 154
(93–253)
161
(99–258)
150
(91–234)
0.45 155
(95–251)
157
(97–257)
158
(103–256)
0.59
Derived indices
BIGTT-Si 9.2
(6.4–12.1)
9.1
(6.2–11.9)
9.8
(7.1–12.4)
0.54 9.2
(6.5–12.1)
9.2
(6.2–12.1)
9.6
(6.0–12.1)
0.37
BIGTT-AIR 1,622
(1,282–2,083)
1,625
(1,290–2,058)
1,634
(1,280–2,092)
0.84 1,618
(1,276–2,048)
1,643
(1,301–2,118)
1,632
(1,310–2,125)
0.05
HOMA-IR 8.2
(5.6–12.6)
8.5
(5.7–13.4)
7.7
(5.5–11.4)
0.24 8.3
(5.7–12.9)
8.4
(5.5–13.1)
8.0
(5.6–12.6)
0.14
Data are means ± standard deviation or median (interquartile range). Values of plasma glucose, serum insulin, HOMA-IR and BIGTT-AIR were 
logarithmically transformed before statistical analysis to obtain normal distribution. All analyses of PKLR rs3020781 were made using an additive 
model (Add), while analyses of NOS1AP rs7539480 were made using a dominant model. Calculated p-values were adjusted for age and sex for BMI 
measures, for sex, age and BMI for serum insulin, plasma glucose and HOMA-IR, and for age for the BIGTT-Si and BIGTT-AIR index. HOMA-IR was 
calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) divided by 22.5. BIGTT-Si and BIGTT-AIR were calculated as 
described [26].BMC Medical Genetics 2008, 9:118 http://www.biomedcentral.com/1471-2350/9/118
Page 6 of 8
(page number not for citation purposes)
rs3020781 may fail as a marker for the functional variant.
Similar may be true for rs7538490, as LD is sparse in the
region where NOS1AP is located. Thus, different LD pat-
terns could explain the lack of association between
rs3020781 and rs7538490 and T2D in our population.
In regards to the identification of T2D susceptibility
genes, the linkage analysis, used for the identification of
PKLR and NOS1AP, has been less successful due to incon-
sistent replication.
However, genome-wide association (GWA) studies have
added to progress in finding common T2D susceptible
gene variants with modest impact on diabetes risk [29-
34], with the identification of non-obvious biological
candidate genes and where replication have been predom-
inantly successful [35-37]. We have investigated results of
available data from GWA studies in web-based databases,
but neither PKLR nor NOS1AP were among the high pri-
ority candidate genes as estimated from genome-wide sig-
nificance levels [29,30]. Two markers in LD with PKLR
rs3020781 were available in the public GWA data, how-
ever, none of these associated with T2D. No markers were
available for NOS1AP rs7538490 [29]. The lack of associ-
ation could either be due to small effect sizes, or the pos-
sibility that the variants represent false positive findings,
thus explaining our failure to demonstrate an association.
Conclusion
In statistically well-powered case-control studies and in
studies of pertinent quantitative phenotypes we failed to
validate the proposed association of the C-allele of
rs3020781 and the T-allele of rs7538490 with T2D or
intermediate phenotypes.
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High-density association mapping and coprehensive tagging of the type 2 
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